ADARx Pharmaceuticals, Inc.
ADARx Pharmaceuticals, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Phase 1 Study of ADX-626 in Healthy Participants on January 22, 2027. There are 8 upcoming events on record.
| Date | Event | Type | Phase |
|---|---|---|---|
| January 22, 2027 | Phase 1 Study of ADX-626 in Healthy Participants | Trial Milestone | Phase 1 |
| November 30, 2027 | STOP-HAE: A Phase 3 Study of ADX-324 in HAE | Trial Milestone | Phase 3 |
| December 31, 2027 | Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients | Trial Milestone | Phase 1/Phase 2 |
| March 31, 2028 | Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients | Trial Milestone | Phase 1/Phase 2 |
| July 10, 2028 | Chinese Adults With Kidney Disease | Trial Milestone | Phase 2 |
| December 31, 2028 | Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease | Trial Milestone | Phase 2 |
| February 28, 2030 | Phase 2 Study of ADX-038 in Participants With Geographic Atrophy | Trial Milestone | Phase 2 |
| June 30, 2030 | Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE) | Trial Milestone | Phase 3 |
Track ADRX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open ADRX in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| September 28, 2026 | 8-K filed: Other event | Filing | — |
| July 31, 2026 | Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension | Trial Milestone | Phase 1 |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.